Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials

BACKGROUND: Recent phase 3 trials have shown an overall survival benefit in metastatic melanoma. We aimed to assess whether progression-free survival (PFS) could be regarded as a reliable surrogate for overall survival through a meta-analysis of randomised trials. METHODS: We systematically reviewed...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Lancet Oncol
Auteurs principaux: Flaherty, Keith T, Hennig, Michael, Lee, Sandra J, Ascierto, Paolo A, Dummer, Reinhard, Eggermont, Alexander M M, Hauschild, Axel, Kefford, Richard, Kirkwood, John M, Long, Georgina V, Lorigan, Paul, Mackensen, Andreas, McArthur, Grant, O'Day, Steven, Patel, Poulam M, Robert, Caroline, Schadendorf, Dirk
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4443445/
https://ncbi.nlm.nih.gov/pubmed/24485879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70007-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires